Reuters logo
7 months ago
BRIEF-Bellerophon Therapeutics announces FDA acceptance of modifications to INOpulse pulmonary arterial hypertension Phase 3 program
January 4, 2017 / 1:06 PM / 7 months ago

BRIEF-Bellerophon Therapeutics announces FDA acceptance of modifications to INOpulse pulmonary arterial hypertension Phase 3 program

1 Min Read

Jan 4 (Reuters) - Bellerophon Therapeutics Inc

* Bellerophon Therapeutics announces FDA acceptance of modifications to INOpulse pulmonary arterial hypertension Phase 3 program Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below